Daiichi Sankyo, the global pharmaceutical company with corporate origins in Japan is seeking research collaborations with UK entities in a number of key areas.
The Department for International Trade is working with Daiichi Sankyo and One Nucleus to organise a free webinar to enable you to learn about the Daiichi Sankyo research priorities and collaboration structures available. The core areas of interest include:
- Novel modality technologies in oncology and CNS (psychiatric and neurodegenerative disease)
- Ex) Target protein degrader (except E3 binder), conditional active antibody (except pH-dependent), next generation of gene therapy etc
- Novel drug delivery technologies to cancer cells or brain after systemic administration
- Ex) Engineered nanoparticle/exosome etc
Novel target or cancer-specific antigen for antibody in oncology
A One Nucleus account is required to sign up for the webinar. Once logged in to the website, you click the button to register and then follow the onscreen instructions to complete registration.